摘要
目的探讨辛伐他汀针对高龄冠心病患者强化降脂治疗的效果和安全性。方法选取高龄冠心病高危患者62例,给予20mg/d的辛伐他汀治疗,按照预定的低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)的达标水平来调整药物的剂量。结果在用药后患者的LDL-C和TC显著降低(P<0.05),在随访结束后,所有患者服用20mg/d的辛伐他汀,其中21例患者的LDL-C和TC分别保持在2.6mmol/L和4.7mmol/L以下,占总人数的33.87%,41例患者的LDL-C和TC分别保持在2.1mmol/L和4.2mmol/L以下,占总人数的66.13%,所有患者均没有不良反应发生。结论辛伐他汀对高龄冠心病高危患者降脂的治疗效果明显,而且安全性良好没有不良反应发生,值得在临床上广泛推广。
Objective To investigate the efficacy and safety of Simvastatin on intensive lipid-lowering treatment in elderly patients with coronary heart disease. Methods 62 cases of elderly patients with high risk of coronary heart disease were se- lected, and given Simvastatin 20 mg/d treatment. The drug dose was regulated according to the scheduled standard level of low-density lipoprotein cholesterol （LDL-C） and total cholesterol （TC）. Results After treatment, the LDL-C and TC level of patients significantly reduced （P 〈 0.05）. After the end of the follow-up, Simvastatin 20 mg/d were taken among all pa- tients, of which 21 cases of LDL-C and TC levels were maintained below 2.6 mmol/L and 4.7mmol/L, accounted for 33.87%. 41 cases of LDL-C and TC levels were maintained below 2.1 mmol/L and 4.2 mmol/L, accounted for 66.13%. All patients had no adverse reaction. Conclusion The curative effect of Simvastatin on lipid-lowering treatment in elderly pa- tients with high risk of coronary heart disease is good and safety, which has no adverse reaction. It is worthy of clinical widely application.
出处
《中国当代医药》
2012年第18期71-72,共2页
China Modern Medicine
关键词
冠心病
辛伐他汀
血脂
老年人
Coronary heart disease
Simvastatin
Lipids
Elderly
